alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit
31.1**





**CERTIFICATIONS**





I, Milton
“Todd” Ault III, as Chief Executive Officer and Principal Financial Officer of
Patient Safety Technologies, Inc., certify that:




1. I have
reviewed this quarterly report on Form 10-Q of Patient Safety Technologies,
Inc.;





2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;





3. Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;





4. The
registrant's other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) for the registrant and have:





(a)
designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries is made known to us by others within those entities, particularly
during the period in which this annual report is being prepared;





(b)
evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and





(c)
disclosed in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and





5. The
registrant's other certifying officer(s) and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of
directors (or persons performing the equivalent functions);





(a) all
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to
adversely affect the registrant's ability to record, process, summarize and
report financial information; and





(b) any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant's internal control over financial
reporting.








May 16,
2005





/s/
Milton “Todd” Ault, III





Milton
“Todd” Ault, III


Chief
Executive Officer


and
Principal Financial Officer
|  |
|--|
|  |
|  |
|  |

|  |                                                                                                            |  |  |  |  |  |  |  |
|--|------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|
|  |                                                                                                            |
|  |                                                                                                            |  |  |
|  |                                                                                                            |
|  |                                                                                                            |  |  |
|  |                                                                                                            |
|  |                                                                                                            |  |
|  | Mission         | Creating Exhibitions | Submitting         Art | Artists Abroad | ART         Exhibitions |  |  |
|  |                                                                                                            |
|  |                                                                                                            |
###### Editorial Note on Part 131

#### Editorial Note:

Nomenclature changes to part 131 appear at 63 FR 14035, Mar. 24, 1998.

#### § 131.25 Whipped cream products containing flavoring or sweetening.

The unqualified name “whipped cream” should not be applied to any product other than one made by whipping the cream that complies with the standards of identity for whipping cream (§§ 131.150 and 131.157 of this chapter). If flavoring and/or sweetening is added, the resulting product is a flavored and/or sweetened whipped cream, and should be so identified.
##### 



Exhibit 32.01

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Thian Hoo Tan, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report of Komag, Incorporated on Form 10-Q for the quarterly period ended June
29, 2003 fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained in such Form
10-Q fairly presents in all material respects the financial condition and
results of operations of Komag, Incorporated.

| |  |                                                   
| |  | --------------------------------------------------
| |  | BY: /s/ Thian Hoo Tan                             
| |  |                                                   
| |  | Name: Thian Hoo Tan
Title: Chief Executive Officer

I, Kathleen A. Bayless, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report of Komag, Incorporated on Form 10-Q for the quarterly period ended June
29, 2003 fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained in such 10-Q
fairly presents in all material respects the financial condition and results of
operations of Komag, Incorporated.

| |  |                                                         
| |  | --------------------------------------------------------
| |  | BY: /s/ Kathleen A. Bayless                             
| |  |                                                         
| |  | Name: Kathleen A. Bayless
Title: Chief Financial Officer

This certification accompanies this Report on Form 10-Q pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required
by such Act, be deemed filed by Komag, Incorporated for purposes of Section 18
of the Security Exchange Act of 1934, as amended. A signed original of this
written statement required by Section 906 has been provided to Komag,
Incorporated and will be retained by Komag, Incorporated and furnished to the
Securities and Exchange Commission or its staff upon request.

44
CENTERS FOR MEDICARE & MEDICAID SERVICES

CMS Product No. 11342

June 2010

Some hospitals do a 

better job of taking 

care of patients than 

others.

Get More Information about Hospital Care

Read, print, or download copies of the following by visiting 

www.medicare.gov, selecting “Resource Locator,” and selecting 

“Publications.”

•	 The “Guide to Choosing a Hospital”

•	 “Your Discharge Planning Checklist”

•	 “Your Medicare Rights and Protections”

•	 “Medicare and Your Hospital Benefits: Getting Started”

Compare Plans and Providers 

Visit www.medicare.gov, select “Resource Locator,” and then 

select one of the following:

•	 Health Plans

•	 Drug Plans

•	 Dialysis Facilities

•	 Home Health Agencies

•	 Nursing Homes

•	 Hospitals
The Official U.S. Government Site for Medicare

Medicare.gov Sign In to MyMedicare.gov

M dire ’ s  Hospita 

Why should I compare hospitals?

Most people check restaurant ratings or read consumer reviews 

before they make a choice. Shouldn’t you also check the quality 

of the hospitals you rely on when you need medical care?

In an emergency, you should go to the nearest hospital. When 

you can plan ahead, you and your doctor should discuss which 

hospital will best meet your health care needs. The information 

on the Hospital Compare Web tool can help you make an 

informed choice. Visit www.medicare.gov/hospital.

What kind of information is on Hospital 

Compare?

Hospital Compare gives you a “snapshot” of the quality of the 

hospitals in your area and around the nation.

•	 How recently-discharged patients responded to a national 

survey about their hospital experience. For example, how well 

their hospital’s doctors and nurses communicate with patients, 

and how well they manage their patients’ pain. 

•	 How often each hospital gives recommended treatments for 

certain common conditions like heart attack, heart failure, 

pneumonia, children’s asthma, and for surgical patients. 

•	 How each hospital’s rates of readmission and 30-day 

mortality (death) rates for certain conditions compare with the 

national rate. 

•	 How a hospital uses outpatient medical imaging tests 

(like CT scans and MRIs).

•	 How many people with Medicare have had certain 

procedures or have been treated for certain conditions at each 

hospital. 

•	 How much Medicare pays a hospital (on average) when the 

hospital performs certain procedures or treats 

certain conditions. 

Soon, Hospital Compare will have information about patient safety 

and hospital-acquired conditions, like infections. Check Hospital 

Compare regularly for updated information. 

Here’s a sample of what you’ll see:
§ 1304.55 Reports by online pharmacies. ( a ) Each online pharmacy shall report to the Administrator the total quantity of each controlled substance that the pharmacy has dispensed each calendar month. The report must include the total quantity of such dispensing by any means, regardless of whether the controlled substances are dispensed by means of the Internet. Thus, such reporting shall include all controlled substances dispensed via Internet transactions, mail-order transactions, face-to-face transactions, or any other means. However, the pharmacy is not required to describe in its report to the Administrator such means of dispensing. Such reporting is required for every calendar month in which the total quantity of controlled substances dispensed by the pharmacy meets or exceeds one of the following thresholds: ( 1 ) 100 or more prescriptions for controlled substances filled; or
( 2 ) 5,000 or more dosage units dispensed of all controlled substances combined.
( b ) Each online pharmacy shall report a negative response if, during a given calendar month, its total dispensing of controlled substances falls below both of the thresholds in paragraph (a) of this section.
( c ) The reporting requirements of this section apply to every pharmacy that, at any time during a calendar month, holds a modified registration authorizing it to operate as an online pharmacy, regardless of whether the online pharmacy dispenses any controlled substances by means of the Internet during the month.
( d ) Reports will be submitted to DEA electronically via online reporting, electronic file upload, or other means as approved by DEA.
( e ) Reports shall be filed every month not later than the fifteenth day of the month succeeding the month for which they are submitted.
( f ) An online pharmacy filing a report under paragraph (a) of this section shall utilize the National Drug Code number assigned to the product under the National Drug Code System of the Food and Drug Administration, and indicate the total number of dosage units dispensed for each such National Drug Code number.
( g ) Records required to be kept under this section must be kept by the registrant for at least two years from the date of such records. The information shall be readily retrievable from the ordinary business records of the registrant and available for inspection and copying by authorized employees of the Administration.
[74 FR 15623, Apr. 6, 2009]
I 

115TH CONGRESS 

1ST SESSION H. R. 930 

To amend title XVIII of the Social Security Act to provide for Medicare 

coverage of certain lymphedema compression treatment items as items 

of durable medical equipment. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 7, 2017 

Mr. REICHERT (for himself, Mr. BLUMENAUER, Mr. LANCE, and Ms. SCHAKOWSKY) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on 

Ways and Means, for a period to be subsequently determined by the 

Speaker, in each case for consideration of such provisions as fall within 

the jurisdiction of the committee concerned 

A BILL 

To amend title XVIII of the Social Security Act to provide 

for Medicare coverage of certain lymphedema compression treatment items as items of durable medical equipment. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Lymphedema Treat5 ment Act’’. 


SSpencer on DSK4SPTVN1PROD with BILLS
2 

•HR 930 IH

1 SEC. 2. MEDICARE COVERAGE OF CERTAIN LYMPHEDEMA 

2 COMPRESSION TREATMENT ITEMS AS ITEMS 

3 OF DURABLE MEDICAL EQUIPMENT. 

4 (a) IN GENERAL.—Section 1861 of the Social Secu5 rity Act (42 U.S.C. 1395x) is amended— 

6 (1) in subsection (n), in the first sentence, by 

7 inserting before the semicolon the following: ‘‘and in8 cludes lymphedema compression treatment items (as 

9 defined in subsection (jjj))’’; and 

10 (2) by adding at the end the following new sub11 section: 

12 ‘‘(jjj) LYMPHEDEMA COMPRESSION TREATMENT

13 ITEMS.—The term ‘lymphedema compression treatment 

14 items’— 

15 ‘‘(1) means, with respect to an individual, com16 pression garments, devices, bandaging systems, com17 ponents, and supplies— 

18 ‘‘(A) that are primarily and customarily 

19 used in the medical treatment of lymphedema; 

20 ‘‘(B) as prescribed by a physician (or a 

21 physician assistant, nurse practitioner, or a 

22 clinical nurse specialist (as those terms are de23 fined in section 1861(aa)(5)) to the extent au24 thorized under State law); and 


SSpencer on DSK4SPTVN1PROD with BILLS
3 

•HR 930 IH

1 ‘‘(C) which would not, other than under 

2 subsection (s)(6), be included as medical and 

3 other health services under this title; and 

4 ‘‘(2) includes— 

5 ‘‘(A) multilayer compression bandaging 

6 systems; 

7 ‘‘(B) custom or standard fit gradient com8 pression garments; 

9 ‘‘(C) non-elastic and low-elastic compres10 sion garments and compression wraps and di11 rectional flow pads; and 

12 ‘‘(D) any other compression garments, 

13 bandaging systems, devices, and aids deter14 mined by the Secretary to be effective in the 

15 prevention or treatment of lymphedema.’’. 

16 (b) EFFECTIVE DATE.—The amendment made by 

17 subsection (a) shall apply to lymphedema compression 

18 treatment items furnished on or after 180 days after the 

19 date of the enactment of this Act. 

Æ 


SSpencer on DSK4SPTVN1PROD with BILLS
### IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 13

- 40985 Conference Calendar

UNITED STATES OF AMERICA , Plaintiff

- Appellee

v. JUAN CARLOS ROBINSON

- JESUS , Defendant

- Appellant
Appeal from the United States District Court for the Southern District of Texas USDC No. 7:13

- CR

- 603

- 1

Before KING, HAYNES, and HIGGINSON, Circuit Judges. PER CURIAM: * Juan Carlos Robinson

- Jesus appeals his 41

- month sentence for illegal presence in the United States following deportation. He challenges the 16

- level enhancement under U.S.S.G. § 2L1.2(b)(1)(A)(ii) imposed for his prior conviction for statutory rape under Tennessee Code Annotated § 39

- 13

- 506(b). According to Robinson

- Jesus, the district court erred by applying the enhancement because § 39

- 13

- 506 criminalizes sexual intercourse with

* Pursuant to 5 TH C IR

. R. 47.5 , the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR

. R. 47.5.4. United States Court of Appeals Fifth Circuit 

### FILED June 17, 2014 Lyle W. Cayce Clerk Case: 13-40985 Document: 00512665965 Page: 1 Date Filed: 06/17/2014No. 13

- 40985 someone under the age of 18 whereas the generic, contemporary definition of “statutory rape”

-- as it i s defined by the Model Penal Code and the laws of various states

-- prohibits intercourse with someone under the age of 16. The Government has filed an unopposed motion for summary affirmance. In United States v. Rodriguez , 711 F.3d 541, 544 (5th Cir.) (en banc), cert. denied , 134 S. Ct. 512 (2013), we held that a “plain

- meaning approach” applies to the determination of the “generic, contemporary” meaning of statutory rape under § 2L1.2(b)(1)(A)(ii). Under this approach, the court looks to the age of

consen t as it is “ defined by statute in the jurisdiction where the prior conviction was obtained ” instead of conducting the “cumbersome” survey of state codes, the Model Penal Code, federal law, and treatises that Robinson

- Jesus urges. See i d

. Robinson

- Jesus c oncedes that the issue i s foreclosed by Rodriguez and raises it merely to preserve it for further review

. Accordingly, t he Government’s motion for summary affirmance is GRANTED, and the judgment of the district court is AFFIRMED. The Government’s alterna tive motion for an extension of time to file a brief is DENIED.

2 Case: 13-40985 Document: 00512665965 Page: 2 Date Filed: 06/17/2014
February 19, 2010

ERRATA

The Fate, Transport, and Ecological Impa cts of Airborne Contaminants in Western National Parks (USA) January 2008

Western Airborne Contaminants A ssessment Project Final Report

Volume I

Page Number Reference Correction

2-23 Whole Fish Contaminant Concentrations for MORA; range of DDTs for Golden Lake Graph shows range of DDTs for Golden Lake from 2.6 ng/g wet weight to the maximum of the range from all the WACAP sites of 50.4 ng/g. The actual maximum of DDTs for Golden is 5.3 ng/g.

2-33 Key to Secondary Park Summary pages, “Vegetation Contaminant Concentration” box in lower right, 3 rd and 4 th lines from bottom (second to last sentence in box) g-HCH is a current-use pesticide, not a historic-use pesticide. Sentence should read: “SOCs are grouped by current-use pesticides (endosulfans, chlorpyrifos,dacthal, g-HCH), historic-use pesticides (aHCH, HCB), polycyclic aromatic hydrocarbons (PAHs), and polychlorinated biphenyls (PCBs).”

3-16 2 nd paragraph, 1 st sentence “metrological” should be “meteorological”

Volume II: Appendices

Page Number Correction

ii NPS WACAP website address for the onlin e location of the WACAP Final Report: The “s” in “studies” should be a capital “S”; http://www.nature.nps.gov/air/Studies/air_toxics/wacap.cfm

3B-21 Last line in Table 3B-15; “refernce” should be “reference”

4A-33 Appendix 4A.11: BAND line: “Ban dolier” should be “Bandelier”

Page 1 of 1
img90163838_0.jpg
     780 Township Line Road  Yardley, PA 19067609-883-3900


Re: Servicer Compliance Statement

The undersigned, a duly authorized officer of Cenlar FSB, as servicer (“the Servicer”) pursuant to applicable servicing agreements governing the securities listed in Exhibit A, does certify that:

1. A review of the Servicer’s activities during the period of 1/1/2023 to 12/31/2023 (the “Reporting Period”) and of the Servicer’s performance under the applicable servicing agreement has been made under my supervision; and


2. To the best of my knowledge, based on such review, the Servicer has fulfilled all of its obligations under the applicable servicing agreement in all material respects throughout the Reporting Period.


The undersigned has duly executed this Certificate this 5th day of March 2024.

img90163838_1.jpg

David C. Schneider President

Cenlar FSB

Mailing Address:Cenlar FSB  425 Phillips Boulevard  Ewing, NJ 08618


---

img90163838_2.jpg








Exhibit A – Securities Covered in Cenlar’s Servicer Compliance Statement



|         |                                      |             |                                    |                       
|-------- | ------------------------------------ | ----------- | ---------------------------------- | ----------------------
|Investor | Servicer                             | Security    | * Period Subserviced by Cenlar FSB | Security Administrator
|RW0      | Redwood Residential Acquisition Corp | SEMT 2012-6 | 1/1 thru 12/31/23                  | Citibank              
|RW2      | Redwood Residential Acquisition Corp | SEMT 2013-2 | 1/1 thru 12/31/23                  | Citibank              
|RW3      | Redwood Residential Acquisition Corp | SEMT 2013-3 | 1/1 thru 12/31/23                  | Citibank              
|RW4      | Redwood Residential Acquisition Corp | SEMT 2013-4 | 1/1 thru 12/31/23                  | Citibank              
|RW5      | Redwood Residential Acquisition Corp | SEMT 2013-5 | 1/1 thru 12/31/23                  | Citibank              
|RW6      | Redwood Residential Acquisition Corp | SEMT 2013-6 | 1/1 thru 12/31/23                  | Citibank              
|RW7      | Redwood Residential Acquisition Corp | SEMT 2013-7 | 1/1 thru 12/31/23                  | Citibank              
|RW8      | Redwood Residential Acquisition Corp | SEMT 2013-8 | 1/1 thru 12/31/23                  | Citibank              






---